Base de dados : MEDLINE
Pesquisa : D03.383.606.450 [Categoria DeCS]
Referências encontradas : 1158 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 116 ir para página                         

  1 / 1158 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28094022
[Au] Autor:Biedron A; Kacinski M; Steczkowska M; Swierczynska A
[Ad] Endereço:Chair of Pediatric and Adolescent Neurology, Department of Pediatric Neurology, Jagiellonian University, Cracow, Poland. Electronic address: aganow7@yahoo.com.
[Ti] Título:A case report of an adolescent with cluster headaches following neck trauma: Coincidence or trigger?
[So] Source:Neurol Neurochir Pol;51(2):170-173, 2017 Mar - Apr.
[Is] ISSN:0028-3843
[Cp] País de publicação:Poland
[La] Idioma:eng
[Ab] Resumo:Posttraumatic headaches usually have tension-type or migraine-like characteristics. A correlation between head trauma and cluster headaches (CH) has been previously reported. CH in children are rare and require thorough differential diagnosis. We present an original case of a 15-year-old boy with cluster headaches associated with allodynia probably evoked by a neck trauma. Severe headache attacks started one month after neck trauma. At the beginning clinical presentation of our patient's headaches was very misleading. Headaches were bilateral and associated with infection. Initial diagnosis of sinusitis was made. During further observation headaches have become unilateral with typical for CH associated symptoms and additionally with allodynia. Other causes of secondary CH like cervicogenic headaches, brain tumor and vascular malformation have been excluded. The boy has undergone prophylactic treatment based on flunarizine and gabapentin with good result. Possible pathogenesis of our patient's headaches has been proposed and diagnostic traps discussed.
[Mh] Termos MeSH primário: Cefaleia Histamínica/etiologia
Lesões do Pescoço/complicações
Ferimentos não Penetrantes/complicações
[Mh] Termos MeSH secundário: Adolescente
Aminas/uso terapêutico
Cefaleia Histamínica/reabilitação
Ácidos Cicloexanocarboxílicos/uso terapêutico
Quimioterapia Combinada
Flunarizina/uso terapêutico
Seguimentos
Seres Humanos
Comunicação Interdisciplinar
Colaboração Intersetorial
Masculino
Lesões do Pescoço/reabilitação
Recidiva
Retratamento
Ferimentos não Penetrantes/reabilitação
Ácido gama-Aminobutírico/uso terapêutico
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Amines); 0 (Cyclohexanecarboxylic Acids); 56-12-2 (gamma-Aminobutyric Acid); 6CW7F3G59X (gabapentin); R7PLA2DM0J (Flunarizine)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170118
[St] Status:MEDLINE


  2 / 1158 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27986997
[Au] Autor:Lin HL; Lin HC; Tseng YF; Chen SC; Hsu CY
[Ad] Endereço:Department of Neurology, Sijhih Cathay General Hospital, No. 2, Ln. 59, Jiancheng Rd., Sijhih Dist, New Taipei City, 221, Taiwan.
[Ti] Título:Risk of parkinsonism induced by flunarizine or cinnarizine: a population-based study.
[So] Source:Eur J Clin Pharmacol;73(3):365-371, 2017 Mar.
[Is] ISSN:1432-1041
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:PURPOSE: This retrospective cohort study used a population-based dataset to test the risk for parkinsonism in patients receiving flunarizine and cinnarizine, compared with matched controls. METHODS: Data were obtained from the National Health Insurance Research Dataset of Taiwan. Patients receiving flunarizine or cinnarizine for more than 1 month between 2000 and 2005 were enrolled. Exclusion criteria included receiving flunarizine, cinnarizine, or antipsychotics for more than 1 month during 1997-1999, a history of neurodegenerative diseases, and an age of less than 30 years. One matched control for each patient was selected. Each participant was followed for diagnosis of parkinsonism within a 3-year observation period. Stroke, diabetes mellitus, total prescription days, and doses of flunarizine or cinnarizine were recorded. RESULTS: The study and control groups consisted of 9830 subjects. In the study group, 280 patients (2.9 %) were diagnosed with parkinsonism with a median observation period of 1.2 years, and 49 participants (0.5 %) were diagnosed in the control group with a median observation period of 1.9 years. The adjusted hazard ratio for parkinsonism among patients receiving flunarizine and cinnarizine was 5.117 (95 % CI = 3.758-6.967). Age, stroke, and diabetes mellitus were significant risk factors, but female sex and total doses of the study drugs were not. CONCLUSIONS: This study demonstrates that flunarizine and cinnarizine significantly increase the risk for parkinsonism. The treatment benefits of these two agents should be balanced with this adverse effect. Physicians must look carefully for early signs of parkinsonism in patients treated with flunarizine and cinnarizine.
[Mh] Termos MeSH primário: Cinarizina/efeitos adversos
Flunarizina/efeitos adversos
Transtornos Parkinsonianos/etiologia
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Estudos de Casos e Controles
Feminino
Seres Humanos
Masculino
Meia-Idade
Estudos Retrospectivos
Fatores de Risco
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
3DI2E1X18L (Cinnarizine); R7PLA2DM0J (Flunarizine)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170920
[Lr] Data última revisão:
170920
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161218
[St] Status:MEDLINE
[do] DOI:10.1007/s00228-016-2181-3


  3 / 1158 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27320656
[Au] Autor:Salmito MC; Duarte JA; Morganti LOG; Brandão PVC; Nakao BH; Villa TR; Ganança FF
[Ad] Endereço:Universidade Federal de São Paulo (UNIFESP), Departamento de Otorrinolaringologia e Cirurgia de Cabeça e Pescoço, São Paulo, SP, Brazil. Electronic address: marciosalmito@yahoo.com.
[Ti] Título:Prophylactic treatment of vestibular migraine.
[So] Source:Braz J Otorhinolaryngol;83(4):404-410, 2017 Jul - Aug.
[Is] ISSN:1808-8686
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Vestibular migraine (VM) is now accepted as a common cause of episodic vertigo. Treatment of VM involves two situations: the vestibular symptom attacks and the period between attacks. For the latter, some prophylaxis methods can be used. The current recommendation is to use the same prophylactic drugs used for migraines, including ß-blockers, antidepressants and anticonvulsants. The recent diagnostic definition of vestibular migraine makes the number of studies on its treatment scarce. OBJECTIVE: To evaluate the efficacy of prophylactic treatment used in patients from a VM outpatient clinic. METHODS: Review of medical records from patients with VM according to the criteria of the Bárány Society/International Headache Society of 2012 criteria. The drugs used in the treatment and treatment response obtained through the visual analog scale (VAS) for dizziness and headache were assessed. The pre and post-treatment VAS scores were compared (the improvement was evaluated together and individually, per drug used). Associations with clinical subgroups of patients were also assessed. RESULTS: Of the 88 assessed records, 47 were eligible. We included patients that met the diagnostic criteria for VM and excluded those whose medical records were illegible and those of patients with other disorders causing dizziness and/or headache that did not meet the 2012 criteria for VM. 80.9% of the patients showed improvement with prophylaxis (p<0.001). Amitriptyline, Flunarizine, Propranolol and Topiramate improved vestibular symptoms (p<0.001) and headache (p<0.015). The four drugs were effective in a statistically significant manner. There was a positive statistical association between the time of vestibular symptoms and clinical improvement. There was no additional benefit in hypertensive patients who used antihypertensive drugs as prophylaxis or depressed patients who used antidepressants in relation to other prophylactic drugs. Drug association did not show statistically significant results in relation to the use of a single drug. CONCLUSIONS: Prophylactic medications used to treat VM improve the symptoms of this disease, but there is no statistically significant difference between the responses of prophylactic drugs. The time of vestibular symptom seems to increase the benefit with prophylactic treatment.
[Mh] Termos MeSH primário: Amitriptilina/uso terapêutico
Flunarizina/uso terapêutico
Frutose/análogos & derivados
Transtornos de Enxaqueca/prevenção & controle
Propranolol/uso terapêutico
Doenças Vestibulares/prevenção & controle
[Mh] Termos MeSH secundário: Adulto
Idoso
Feminino
Frutose/uso terapêutico
Seres Humanos
Estudos Longitudinais
Masculino
Meia-Idade
Estudos Retrospectivos
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0H73WJJ391 (topiramate); 1806D8D52K (Amitriptyline); 30237-26-4 (Fructose); 9Y8NXQ24VQ (Propranolol); R7PLA2DM0J (Flunarizine)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170731
[Lr] Data última revisão:
170731
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160621
[St] Status:MEDLINE


  4 / 1158 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27306581
[Au] Autor:Lai KL; Niddam DM; Fuh JL; Chen SP; Wang YF; Chen WT; Wu JC; Wang SJ
[Ad] Endereço:Department of Neurology, Taipei Municipal Gandau Hospital, Taipei, Taiwan.
[Ti] Título:Flunarizine versus topiramate for chronic migraine prophylaxis: a randomized trial.
[So] Source:Acta Neurol Scand;135(4):476-483, 2017 Apr.
[Is] ISSN:1600-0404
[Cp] País de publicação:Denmark
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: Chronic migraine (CM) is a prevalent and devastating disorder with limited therapeutic options. This study explored the efficacy of 10 mg/d flunarizine for CM prophylaxis as compared with 50 mg/d topiramate. METHODS: We conducted a prospective, randomized, open-label, blinded-endpoint trial. Patients with CM were randomized to flunarizine and topiramate treatment. The primary outcomes assessed were the reductions in the total numbers of headache days and migraine days after 8 weeks of treatment. Secondary outcomes were reductions in the numbers of days of acute abortive medication intake and acute abortive medication tablets taken, and the 50% responder rate. RESULTS: Sixty-two subjects were randomized (n=31/group). Patients treated with flunarizine showed significant reductions in the numbers of total headache days (-4.9 vs -2.3, P=.012) and migraine days (-4.3 vs -1.4, P=.001) compared with those treated with topiramate. Patients treated with flunarizine also showed significant reductions in the numbers of days of acute abortive medication intake (-2.3 vs -0.2, P=.005) and acute abortive medication tablets taken (-4.6 vs -0.5, P=.005) and had a higher 50% responder rate in terms of total headache days (58.6% vs 25.9%, P=.013) and migraine days (75.9% vs 29.6%, P=.001), compared with topiramate-treated patients. Flunarizine was generally well tolerated and had a safety profile comparable to that of topiramate. CONCLUSIONS: Our results suggest that, in an 8-week study, 10 mg/d flunarizine is more effective than 50 mg/d topiramate for CM prophylaxis.
[Mh] Termos MeSH primário: Anticonvulsivantes/uso terapêutico
Flunarizina/uso terapêutico
Frutose/análogos & derivados
Transtornos de Enxaqueca/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Anticonvulsivantes/administração & dosagem
Anticonvulsivantes/efeitos adversos
Método Duplo-Cego
Feminino
Flunarizina/administração & dosagem
Flunarizina/efeitos adversos
Frutose/administração & dosagem
Frutose/efeitos adversos
Frutose/uso terapêutico
Seres Humanos
Masculino
Meia-Idade
Transtornos de Enxaqueca/prevenção & controle
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anticonvulsants); 0H73WJJ391 (topiramate); 30237-26-4 (Fructose); R7PLA2DM0J (Flunarizine)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170508
[Lr] Data última revisão:
170508
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160617
[St] Status:MEDLINE
[do] DOI:10.1111/ane.12626


  5 / 1158 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:27618916
[Au] Autor:Cao K; Han F; Lin A; Yang W; Zhao J; Zhang H; Ding Y; Xie W; Xu Y; Yu T; Wang X; Yang X; Zhou J; Hou Q; Yu L; Gao Y
[Ad] Endereço:Department of Neurology, Dongzhimen Hospital, Beijing University of Chinese Medicine, No.5 Haiyun Cang, Dong Cheng District, Beijing, China.
[Ti] Título:Zhengtian Capsule versus flunarizine in patients with migraine: a multi-center, double-blind, double-dummy, randomized controlled, non-inferior clinical trial.
[So] Source:BMC Complement Altern Med;16:356, 2016 Sep 13.
[Is] ISSN:1472-6882
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The primary objective of this study was to assess whether Zhengtian Capsule was non-inferior to flunarizine in efficacy and safety profile for prevention of migraine in adults. METHODS: This was a double-dummy, double-blind, multicenter, positive drug (flunarizine), parallel randomized controlled, non-inferior clinical trial. Patients (n = 360) were randomized in a 1:1 to receive either Zhengtian Capsule or flunarizine, including 12 weeks' intervention and 4 weeks' follow-up. The primary outcome measure was responder rate (defined as the percentage of subjects in a treatment group with 50 % or greater reduction in attack frequency during treatment compared with the baseline period). The secondary outcome measures included migraine attack frequency, the number of migraine days, pain evaluated by visual analogue scale (VAS) score, duration of migraine attacks, the times of using analgesics, patient-reported outcome (PRO) measure of migraine and the scores of short-form 36 Health Survey Scale (SF-36). Weight variation in both groups was also evaluated. Adverse events were monitored throughout the trial. RESULTS: Zhengtian Capsule was non-inferior to flunarizine in responder rate at week 12 and follow-up period (P = 0.002, P < 0.001). There was fewer migraine days in Zhengtian Capsule group at follow-up period compared with flunarizine (P = 0.001). For the total duration of migraine attacks, there was significant group difference at week 4 which favored the control group (P = 0.009). For the total score of PRO scale, there was statistical difference between the two groups at follow-up period (P = 0.021). There were also group differences between the two groups in the dimensions of somatization symptoms at week 4 (P = 0.022) and functional status at week 12 and follow-up period (P < 0.001, P < 0.001). However, there were no significant differences between the two groups in migraine attack frequency, VAS scores reduction, consumption of acute pain drugs and the dimension scores of SF-36 at any time interval of the treatment period (P > 0.05). No severe adverse events occurred in the trial. Flunarizine was found associated with a weight gain. CONCLUSION: Zhengtian Capsule was non-inferior to flunarizine with regard to the primary endpoint. In addition, it could reduce migraine days and improve the functional status and somatization symptoms of migraine patients with good safety profile. TRIAL REGISTRATION: This trial was registered at Chinese Clinical Trial Register (ChiCTR), ChiCTR-TRC-13004412.
[Mh] Termos MeSH primário: Analgésicos/uso terapêutico
Medicamentos de Ervas Chinesas/uso terapêutico
Flunarizina/uso terapêutico
Transtornos de Enxaqueca/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Analgésicos/efeitos adversos
Método Duplo-Cego
Medicamentos de Ervas Chinesas/efeitos adversos
Feminino
Flunarizina/efeitos adversos
Seres Humanos
Masculino
Meia-Idade
Medição da Dor
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Analgesics); 0 (Drugs, Chinese Herbal); R7PLA2DM0J (Flunarizine)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170222
[Lr] Data última revisão:
170222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160914
[St] Status:MEDLINE
[do] DOI:10.1186/s12906-016-1321-8


  6 / 1158 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27008799
[Au] Autor:Prashanth KN; Swamy N; Basavaiah K
[Ti] Título:INVESTIGATION AND OPTIMIZATION OF TITRIMETRIC AND SPECTROPHOTOMETRIC METHODS FOR THE ASSAY OF FLUNARIZINE DIHYDROCHLORIDE USING IN SITU BROMINE.
[So] Source:Acta Pol Pharm;73(1):35-45, 2016 Jan-Feb.
[Is] ISSN:0001-6837
[Cp] País de publicação:Poland
[La] Idioma:eng
[Ab] Resumo:Three indirect methods for the assay of flunarizine dihydrochloride (FNH) in bulk drug and commercial formulation based on titrimetric and spectrophotometric techniques using bromate-bromide mixture are described. In titrimetry, a measured excess of bromate-bromide mixture is added to an acidified solution of FNH and the unreacted bromine is determined iodometrically (method A). Spectrophotometry involves the addition of a known excess of bromate-bromide mixture to FNH in acid medium followed by estimation of unreacted bromine by its reaction with excess iodide and the liberated iodine (I3⁻) is either measured at 370 nm (method B) or liberated iodine reacted with starch followed by the measurement of the blue colored starch-iodide complex at 575 run (method C). Titrimetric method is applicable over the range 4.5-30.0 mg FNH (method A), and the reaction stoichiometry is found to be 1:2 (FNH:KBrO3). The spectrophotometric methods are applicable over the concentration ranges 0.8-16.0 µg/mL and 0.4-8.0 µg/mL FNH for method B and method C, respectively. The molar absorptivities are calculated to be 2.83 x 104 and 4.96 x 104 L mol⁻¹cm⁻¹ for method B and method C, respectively, and the corresponding Sandell sensitivity values are 0.0168 and 0.0096 µg cm⁻². The proposed methods have been applied successfully for the determination of FNH in pure form and in its dosage form and the results were compared with those of a literature method by applying the Student's t-test and F-test.
[Mh] Termos MeSH primário: Flunarizina/análise
Espectrofotometria/métodos
[Mh] Termos MeSH secundário: Bromo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
R7PLA2DM0J (Flunarizine); SBV4XY874G (Bromine)
[Em] Mês de entrada:1604
[Cu] Atualização por classe:160324
[Lr] Data última revisão:
160324
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160325
[St] Status:MEDLINE


  7 / 1158 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26389725
[Au] Autor:Prigozhin DM; Modis Y
[Ad] Endereço:Department of Medicine, University of Cambridge, MRC Laboratory of Molecular Biology, Cambridge, UK.
[Ti] Título:Flunarizine arrests hepatitis C virus membrane fusion.
[So] Source:Hepatology;63(1):14-6, 2016 Jan.
[Is] ISSN:1527-3350
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Flunarizina/farmacologia
Hepacivirus/efeitos dos fármacos
Proteínas Virais de Fusão/efeitos dos fármacos
Internalização do Vírus/efeitos dos fármacos
[Mh] Termos MeSH secundário: Seres Humanos
[Pt] Tipo de publicação:COMMENT; EDITORIAL
[Nm] Nome de substância:
0 (Viral Fusion Proteins); R7PLA2DM0J (Flunarizine)
[Em] Mês de entrada:1605
[Cu] Atualização por classe:170922
[Lr] Data última revisão:
170922
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150922
[St] Status:MEDLINE
[do] DOI:10.1002/hep.28224


  8 / 1158 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26248546
[Au] Autor:Perin PM; Haid S; Brown RJ; Doerrbecker J; Schulze K; Zeilinger C; von Schaewen M; Heller B; Vercauteren K; Luxenburger E; Baktash YM; Vondran FW; Speerstra S; Awadh A; Mukhtarov F; Schang LM; Kirschning A; Müller R; Guzman CA; Kaderali L; Randall G; Meuleman P; Ploss A; Pietschmann T
[Ad] Endereço:Institute of Experimental Virology, TWINCORE, Centre for Experimental and Clinical Infection Research; a joint venture between the Medical School Hannover and the Helmholtz Centre for Infection Research, Hannover, Germany.
[Ti] Título:Flunarizine prevents hepatitis C virus membrane fusion in a genotype-dependent manner by targeting the potential fusion peptide within E1.
[So] Source:Hepatology;63(1):49-62, 2016 Jan.
[Is] ISSN:1527-3350
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:UNLABELLED: To explore mechanisms of hepatitis C viral (HCV) replication we screened a compound library including licensed drugs. Flunarizine, a diphenylmethylpiperazine used to treat migraine, inhibited HCV cell entry in vitro and in vivo in a genotype-dependent fashion. Analysis of mosaic viruses between susceptible and resistant strains revealed that E1 and E2 glycoproteins confer susceptibility to flunarizine. Time of addition experiments and single particle tracking of HCV demonstrated that flunarizine specifically prevents membrane fusion. Related phenothiazines and pimozide also inhibited HCV infection and preferentially targeted HCV genotype 2 viruses. However, phenothiazines and pimozide exhibited improved genotype coverage including the difficult to treat genotype 3. Flunarizine-resistant HCV carried mutations within the alleged fusion peptide and displayed cross-resistance to these compounds, indicating that these drugs have a common mode of action. CONCLUSION: These observations reveal novel details about HCV membrane fusion; moreover, flunarizine and related compounds represent first-in-class HCV fusion inhibitors that merit consideration for repurposing as a cost-effective component of HCV combination therapies.
[Mh] Termos MeSH primário: Flunarizina/farmacologia
Hepacivirus/efeitos dos fármacos
Proteínas Virais de Fusão/efeitos dos fármacos
Internalização do Vírus/efeitos dos fármacos
[Mh] Termos MeSH secundário: Células Cultivadas
Genótipo
Hepacivirus/genética
Seres Humanos
Proteínas Virais de Fusão/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Viral Fusion Proteins); R7PLA2DM0J (Flunarizine)
[Em] Mês de entrada:1605
[Cu] Atualização por classe:170101
[Lr] Data última revisão:
170101
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150808
[St] Status:MEDLINE
[do] DOI:10.1002/hep.28111


  9 / 1158 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:26108905
[Au] Autor:Muriel V; Garcia-Molina A; Aparicio-Lopez C; Ensenat A; Roig-Rovira T
[Ad] Endereço:Institut de Neurorehabilitacio Guttmann-UAB, 08916 Badalona, Espana.
[Ti] Título:[Neuropsychological deficits in alternating hemiplegia of childhood: a case study].
[Ti] Título:Deficits neuropsicologicos en la hemiplejia alternante infantil: estudio de un caso..
[So] Source:Rev Neurol;61(1):25-8, 2015 Jul 01.
[Is] ISSN:1576-6578
[Cp] País de publicação:Spain
[La] Idioma:spa
[Ab] Resumo:INTRODUCTION: Alternating hemiplegic of childhood is a predominantly sporadic neurodevelopmental syndrome of uncertain etiology, characterized by alternating transient attacks of hemiplegia. Additional features include tonic fits, dystonic posturing, ocular motor abnormalities and deficits in cognitive functioning. CASE REPORT: A girl of 7 years-old with alternating hemiplegic of childhood. The first symptoms debut at 17 months of age in the form of lower limb weakness, migraine, nystagmus and hemiplegic crisis alternating both hemibodies. We administrate the Wechsler Intelligence Scale for Children IV (WISC-IV), the Conners Continuous Performance Test II (CPT-II), the Conners scales for parents (CPRS-48) and teachers (CTRS-28) and the Behavior Rating Inventory Executive Function (BRIEF). CONCLUSIONS: In our study we found deficits in sustained attention, reduced speed of information processing, and difficulties in understanding, speaking and working memory. In addition, parents and teachers reported behavioral disturbances, difficulties inhibition capability, in self-control and in regulating emotions.
[Mh] Termos MeSH primário: Hemiplegia/psicologia
[Mh] Termos MeSH secundário: Atenção
Criança
Transtornos do Comportamento Infantil/etiologia
Compreensão
Emoções
Feminino
Flunarizina/uso terapêutico
Hemiplegia/diagnóstico
Hemiplegia/tratamento farmacológico
Seres Humanos
Transtornos da Memória/etiologia
Memória de Curto Prazo
Processos Mentais
Neuroimagem
Exame Neurológico
Testes Neuropsicológicos
Desempenho Psicomotor
Índice de Gravidade de Doença
Distúrbios da Fala/etiologia
[Pt] Tipo de publicação:CASE REPORTS; ENGLISH ABSTRACT; JOURNAL ARTICLE
[Nm] Nome de substância:
R7PLA2DM0J (Flunarizine)
[Em] Mês de entrada:1604
[Cu] Atualização por classe:150625
[Lr] Data última revisão:
150625
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150626
[St] Status:MEDLINE


  10 / 1158 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
[PMID]:26061748
[Au] Autor:Faria CC; Agnihotri S; Mack SC; Golbourn BJ; Diaz RJ; Olsen S; Bryant M; Bebenek M; Wang X; Bertrand KC; Kushida M; Head R; Clark I; Dirks P; Smith CA; Taylor MD; Rutka JT
[Ad] Endereço:Division of Neurosurgery, Department of Surgery, The Hospital for Sick Children, Toronto, Canada.
[Ti] Título:Identification of alsterpaullone as a novel small molecule inhibitor to target group 3 medulloblastoma.
[So] Source:Oncotarget;6(25):21718-29, 2015 Aug 28.
[Is] ISSN:1949-2553
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Advances in the molecular biology of medulloblastoma revealed four genetically and clinically distinct subgroups. Group 3 medulloblastomas are characterized by frequent amplifications of the oncogene MYC, a high incidence of metastasis, and poor prognosis despite aggressive therapy. We investigated several potential small molecule inhibitors to target Group 3 medulloblastomas based on gene expression data using an in silico drug screen. The Connectivity Map (C-MAP) analysis identified piperlongumine as the top candidate drug for non-WNT medulloblastomas and the cyclin-dependent kinase (CDK) inhibitor alsterpaullone as the compound predicted to have specific antitumor activity against Group 3 medulloblastomas. To validate our findings we used these inhibitors against established Group 3 medulloblastoma cell lines. The C-MAP predicted drugs reduced cell proliferation in vitro and increased survival in Group 3 medulloblastoma xenografts. Alsterpaullone had the highest efficacy in Group 3 medulloblastoma cells. Genomic profiling of Group 3 medulloblastoma cells treated with alsterpaullone confirmed inhibition of cell cycle-related genes, and down-regulation of MYC. Our results demonstrate the preclinical efficacy of using a targeted therapy approach for Group 3 medulloblastomas. Specifically, we provide rationale for advancing alsterpaullone as a targeted therapy in Group 3 medulloblastoma.
[Mh] Termos MeSH primário: Antineoplásicos/química
Benzazepinas/química
Ensaios de Seleção de Medicamentos Antitumorais
Indóis/química
Meduloblastoma/tratamento farmacológico
[Mh] Termos MeSH secundário: Acetofenonas/química
Animais
Benzopiranos/química
Neoplasias Encefálicas/tratamento farmacológico
Linhagem Celular
Proliferação Celular
Quinases Ciclina-Dependentes/antagonistas & inibidores
Dioxolanos/química
Flunarizina/química
Perfilação da Expressão Gênica
Genômica
Seres Humanos
Camundongos
Metástase Neoplásica
Transplante de Neoplasias
Prognóstico
Proteínas Proto-Oncogênicas c-myc/metabolismo
RNA/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Acetophenones); 0 (Antineoplastic Agents); 0 (Benzazepines); 0 (Benzopyrans); 0 (Dioxolanes); 0 (Indoles); 0 (MYC protein, human); 0 (Proto-Oncogene Proteins c-myc); 0 (alsterpaullone); 63231-63-0 (RNA); E29LP3ZMUH (rottlerin); EC 2.7.11.22 (Cyclin-Dependent Kinases); HN39MC8KIO (piperlonguminine); R7PLA2DM0J (Flunarizine)
[Em] Mês de entrada:1606
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150611
[St] Status:MEDLINE



página 1 de 116 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde